Median age (IQR), years
|
40 (33, 46)
|
41 (35, 47)
|
39 (33, 46)
|
41 (36, 49)
|
Male sex
|
2195 (85%)
|
394 (81%)
|
1690 (85%)
|
111 (83%)
|
African/Caribbean ethnicity a
|
368 (24%)
|
17 (5%)
|
344 (29%)
|
17 (27%)
|
Median eGFR (IQR), mL/min/1.73 m2
|
105 (92, 116)
|
103 (91, 114)
|
105 (92, 117)
|
106 (96, 115)
|
Injection drug use as HIV risk factor b
|
389 (18%)
|
302 (69%)
|
83 (5%)
|
4 (4%)
|
Median CD4+ cell count (IQR), cells/μL
|
210 (102, 318)
|
190 (80, 290)
|
220 (110, 323)
|
200 (100, 319)
|
Median HIV viral load (IQR), log10 copies/mL
|
4.9 (4.4, 5.2)
|
4.9 (4.4, 5.1)
|
4.9 (4.4, 5.2)
|
4.9 (4.4, 5.2)
|
Previous AIDS-defining event c
|
450 (19%)
|
99 (22%)
|
331 (19%)
|
20 (18%)
|
Tenofovir use
|
1410 (54%)
|
227 (47%)
|
1111 (56%)
|
72 (54%)
|
Atazanavir use
|
666 (26%)
|
144 (30%)
|
494 (25%)
|
28 (21%)
|
Lopinavir use
|
471 (18%)
|
99 (20%)
|
347 (18%)
|
25 (19%)
|
Median year of cART initiation (IQR)
|
2007 (2004, 2009)
|
2006 (2003, 2009)
|
2008 (2004, 2009)
|
2008 (2004, 2010)
|
Liver fibrosis (APRI ≥1.5) d
|
145 (7%)
|
69 (17%)
|
71 (5%)
|
5 (6%)
|
Diabetes e
|
119 (5%)
|
26 (6%)
|
89 (5%)
|
4 (3%)
|
Hypertension f
|
74 (12%)
|
13 (15%)
|
59 (12%)
|
2 (8%)
|
Cohort province
|
British Columbia
|
1103 (43%)
|
307 (63%)
|
738 (37%)
|
58 (44%)
|
Ontario
|
838 (32%)
|
110 (23%)
|
694 (35%)
|
34 (26%)
|
Québec
|
654 (25%)
|
67 (14%)
|
546 (28%)
|
41 (31%)
|